Ted Budd: “To lower the cost of prescription drugs, we need to enable low-cost biological drugs to reach consumers faster.”

Limiting regulatory risks for companies interested in going public is essential to keeping U.S. financial markets the best in the world. Far too many companies are unwilling to go public because regulatory barriers are too costly, complex…

“For that reason,” Budd continued, “I will vote against any supplemental appropriations package that does not include additional funding for Western North Carolina.”

But now here we are, nine months later, we still haven’t seen the reimbursements.

For that reason, I will vote against any supplemental appropriations package that does not include additional funding for Western North Carolina.